In:
Journal of Gastroenterology and Hepatology, Wiley, Vol. 29, No. 6 ( 2014-06), p. 1273-1278
Abstract:
The purpose of the present study was to determine whether lamivudine in combination with transarterial chemoembolization ( TACE ) could reduce hepatitis B virus ( HBV ) activation and improve the survival of patients with hepatocellular carcinoma ( HCC ). Methods From J uly 2008 to O ctober 2011, a total of 181 consecutive HBV ‐related HCC patients undergoing TACE were randomized to two groups (92: lamivudine, 89: control). Follow up was every 3 months. Primary and secondary end‐points were time to progression ( TTP ) and overall survival ( OS ), respectively, both of which were evaluated by the Kaplan–Meier technique and summarized by the hazard ratio. Results The level of HBV‐DNA became undetectable in 42 (45.6%) patients in the lamivudine group, compared with 10 (11.2%) in the control group ( P 〈 0.001). The median TTP was 8.2 months in lamivudine group and 4.3 months in control group ( P = 0.005), and lamivudine therapy was an independent protective factor related to TTP ( P = 0.006). Moreover, 1‐, 2‐, and 3‐year survival rates were 83%, 69%, and 58% in lamivudine group and 60%, 48%, and 48% in control group, respectively ( P = 0.002). With multivariate Cox regression model, lamivudine therapy ( P = 0.002) and α‐fetoprotein ( AFP ) level ( P = 0.003) were two independent predictors for OS . Conclusion Lamivudine therapy could reduce HBV activation and improve survival of HCC patients treated with TACE . Lamivudine therapy and AFP level are two independent factors affecting OS .
Type of Medium:
Online Resource
ISSN:
0815-9319
,
1440-1746
DOI:
10.1111/jgh.2014.29.issue-6
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2006782-3
Permalink